Page last updated: 2024-12-06
2,4,7,9-tetramethyl-5-decyne-4,7-diol
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
2,4,7,9-tetramethyl-5-decyne-4,7-diol: a non-ionic surfactant; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
| ID Source | ID |
|---|---|
| PubMed CID | 31362 |
| CHEMBL ID | 2143891 |
| SCHEMBL ID | 57923 |
| MeSH ID | M0543806 |
Synonyms (67)
| Synonym |
|---|
| AC-16744 |
| AKOS015841724 |
| nsc-5630 |
| nsc5630 |
| 126-86-3 |
| 2,7,9-tetramethyl-5-decyne-4,7-diol |
| surfynol 104a |
| surfynol 104 |
| 5-decyne-4, 2,4,7,9-tetramethyl- |
| syrfynol 104 |
| surfynol 104e |
| 1,4-dimethylbutynediol |
| 2,4,7,9-tetramethyldec-5-yne-4,7-diol |
| 5-decyne-4,7-diol, 2,4,7,9-tetramethyl- |
| NCGC00164119-01 |
| 2,4,7,9-tetramethyl-5-decyn-4,7-diol |
| T0724 |
| lxofypkxcsultl-uhfffaoya |
| 2,4,7,9-tetramethyl-5-decyne-4,7-diol |
| 4,7-dihydroxy-2,4,7,9-tetramethyl-5-decyne |
| inchi=1/c14h26o2/c1-11(2)9-13(5,15)7-8-14(6,16)10-12(3)4/h11-12,15-16h,9-10h2,1-6h3 |
| NCGC00164119-02 |
| NCGC00164119-03 |
| ai3-07159 |
| surynol 104 |
| hsdb 5612 |
| einecs 204-809-1 |
| ec 204-809-1 |
| tetramethyl decynediol |
| 1,4-diisobutyl-1,4-dimethylbutynediol |
| nsc 5630 |
| b9y126ny8k , |
| unii-b9y126ny8k |
| 5-decyne-4,7-diol-2,4,7,9-tetramethyl |
| cas-126-86-3 |
| dtxcid307041 |
| NCGC00259197-01 |
| dtxsid7027041 , |
| tox21_300559 |
| tox21_201648 |
| NCGC00254519-01 |
| FT-0609935 |
| surfynol 104pa |
| zetasperse 1200 |
| surfynol 104bc |
| surfynol 104h |
| olfine pd 301 |
| surfynol tg |
| olfine ak 02 |
| acetylenol e 00 |
| SCHEMBL57923 |
| CHEMBL2143891 |
| Q-200179 |
| J-660011 |
| 2,4,7,9-tetremathyl-5-decyne-4,7-diol |
| surfynol pg-50 (salt/mix) |
| surfynol tg-e (salt/mix) |
| surfynol 104pg (salt/mix) |
| surfynol pc (salt/mix) |
| tetramethyl decynediol [inci] |
| tetramethyl decynediol [hsdb] |
| tmdd |
| mfcd00008942 |
| 2.4.7.9-tetramethyl-5-decyne-4,7-diol |
| CS-0077080 |
| Q2384542 |
| 2,4,7,9-tetramethyl-5-decyn-4,7 diol |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Protein Targets (23)
Potency Measurements
| Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| pregnane X receptor | Rattus norvegicus (Norway rat) | Potency | 44.6684 | 0.0251 | 27.9203 | 501.1870 | AID651751 |
| RAR-related orphan receptor gamma | Mus musculus (house mouse) | Potency | 41.6961 | 0.0060 | 38.0041 | 19,952.5996 | AID1159521; AID1159523 |
| SMAD family member 2 | Homo sapiens (human) | Potency | 38.9402 | 0.1737 | 34.3047 | 61.8120 | AID1346859; AID1346924 |
| SMAD family member 3 | Homo sapiens (human) | Potency | 38.9402 | 0.1737 | 34.3047 | 61.8120 | AID1346859; AID1346924 |
| GLI family zinc finger 3 | Homo sapiens (human) | Potency | 9.4918 | 0.0007 | 14.5928 | 83.7951 | AID1259369 |
| AR protein | Homo sapiens (human) | Potency | 59.6351 | 0.0002 | 21.2231 | 8,912.5098 | AID1259243; AID1259247; AID743035; AID743054 |
| nuclear receptor subfamily 1, group I, member 3 | Homo sapiens (human) | Potency | 37.8283 | 0.0010 | 22.6508 | 76.6163 | AID1224838; AID1224893 |
| progesterone receptor | Homo sapiens (human) | Potency | 76.9588 | 0.0004 | 17.9460 | 75.1148 | AID1346795 |
| retinoic acid nuclear receptor alpha variant 1 | Homo sapiens (human) | Potency | 36.1575 | 0.0030 | 41.6115 | 22,387.1992 | AID1159552; AID1159555 |
| retinoid X nuclear receptor alpha | Homo sapiens (human) | Potency | 8.7176 | 0.0008 | 17.5051 | 59.3239 | AID1159527; AID1159531 |
| estrogen-related nuclear receptor alpha | Homo sapiens (human) | Potency | 36.4901 | 0.0015 | 30.6073 | 15,848.9004 | AID1224841; AID1224848; AID1224849; AID1259403 |
| pregnane X nuclear receptor | Homo sapiens (human) | Potency | 27.7326 | 0.0054 | 28.0263 | 1,258.9301 | AID1346982; AID720659 |
| estrogen nuclear receptor alpha | Homo sapiens (human) | Potency | 46.9493 | 0.0002 | 29.3054 | 16,493.5996 | AID1259244; AID1259248; AID743069; AID743079; AID743080; AID743091 |
| peroxisome proliferator activated receptor gamma | Homo sapiens (human) | Potency | 30.8956 | 0.0010 | 19.4141 | 70.9645 | AID743191 |
| cytochrome P450, family 19, subfamily A, polypeptide 1, isoform CRA_a | Homo sapiens (human) | Potency | 47.1328 | 0.0017 | 23.8393 | 78.1014 | AID743083 |
| nuclear factor of kappa light polypeptide gene enhancer in B-cells 1 (p105), isoform CRA_a | Homo sapiens (human) | Potency | 21.4316 | 19.7391 | 45.9784 | 64.9432 | AID1159509 |
| Caspase-7 | Cricetulus griseus (Chinese hamster) | Potency | 42.3984 | 0.0067 | 23.4960 | 68.5896 | AID1346980 |
| caspase-3 | Cricetulus griseus (Chinese hamster) | Potency | 42.3984 | 0.0067 | 23.4960 | 68.5896 | AID1346980 |
| thyroid hormone receptor beta isoform 2 | Rattus norvegicus (Norway rat) | Potency | 53.3764 | 0.0003 | 23.4451 | 159.6830 | AID743067 |
| nuclear factor erythroid 2-related factor 2 isoform 1 | Homo sapiens (human) | Potency | 71.1786 | 0.0006 | 27.2152 | 1,122.0200 | AID743219 |
| Voltage-dependent calcium channel gamma-2 subunit | Mus musculus (house mouse) | Potency | 58.0807 | 0.0015 | 57.7890 | 15,848.9004 | AID1259244 |
| Cellular tumor antigen p53 | Homo sapiens (human) | Potency | 75.3962 | 0.0023 | 19.5956 | 74.0614 | AID651631 |
| Glutamate receptor 2 | Rattus norvegicus (Norway rat) | Potency | 58.0807 | 0.0015 | 51.7393 | 15,848.9004 | AID1259244 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
Biological Processes (124)
Molecular Functions (34)
Ceullar Components (20)
Research
Studies (7)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 6 (85.71) | 24.3611 |
| 2020's | 1 (14.29) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Market Indicators
Research Demand Index: 31.52
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (31.52) All Compounds (24.57) |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 7 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||